Wonik Corporation

Wonik Corporation

KKRX:032940
6,750.00
KRW
-110.00
(-1.60%)
530.66EPS
17.09P/E
161.92BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4,788.41
4,489.64
4,095.15
4,602.15
4,774.33
4,910.1
5,035.64
4,810.52
5,203.96
5,941.16
7,155.74
7,625.02
8,282.58
8,305.24
Basic EPS, GAAP
396.81
18.84
-63.7
5,028.1
978.88
-4,260
2,037
4,365
1,565.88
2,102
-95
1,162
632
520.82
Free Cash Flow per Basic Share
-199.81
-55.26
-63.92
-187.71
-121.63
-93.28
242.52
376.49
328.43
-901.09
513.4
390.76
-560.19
-429.44
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3,311.95
3,128.76
2,973.98
7,771.06
8,771.46
3,716.35
5,733
10,207.23
11,823.44
13,943.42
13,788.59
14,920.38
15,604.65
15,702.59
Tangible Book Value per Share
3,223.88
3,064.37
2,838.7
7,679.81
8,692.01
3,666.12
5,683.87
10,160.08
11,736.17
13,270.54
13,091.62
14,223.18
14,967.52
15,066.81
Basic Weighted Avg Shares
12
13
14
14
14
16
18
18
18
18
18
18
18
18
Sales/Revenue/Turnover
57,257
56,839
56,267
64,804
67,244
80,295
90,386
87,494
94,675
108,089
129,877
138,735
150,735
151,099
Operating Margin (%)
0.45
0.81
-5.28
4.54
0.63
3.47
4.9
5.22
7.31
6.85
9.61
6.72
5.92
5.93
Depreciation Expense
945
966
1,230
1,546
1,473
1,764
2,329
2,456
2,438
2,316
2,103
2,078
2,305
2,433
Net Income, GAAP
4,745
239
-875
70,802
13,787
-69,664
36,563
79,391
28,488
38,242
-1,724
21,142
11,502
9,475
Effective Tax Rate (%)
53.19
75.53
- -
20.86
22.77
- -
21.75
22.07
20.62
11.24
141.35
- -
20.05
21.45
Profit Margin (%)
8.29
0.42
-1.56
109.26
20.5
-86.76
40.45
90.74
30.09
35.38
-1.33
15.24
7.63
6.27
Working Capital
-32,821
-26,038
-41,804
-20,323
-43,298
-24,510
-15,529
-21,463
-11,142
-22,517
-18,633
-2,416
-3,314
-3,919
LT Debt
- -
- -
1,947
859
1,074
257
3,951
2,203
9,762
7,712
215
13,674
16,052
15,875
Total Equity
35,573
38,179
44,183
110,524
125,643
67,993
105,143
186,565
216,193
255,185
252,891
273,820
286,616
288,513
Return on Invested Capital (%)
0.09
0.13
- -
1.46
0.19
- -
2.51
1.89
2.18
2.32
-1.68
- -
2.17
2.09
Return on Capital (%)
6.85
0.91
- -
55.47
8.22
- -
29
42.76
12.22
14.02
-0.99
- -
3.9
3.18
Return on Common Equity (%)
12.74
0.58
-2.08
93.59
11.84
-73.27
42.78
54.76
14.22
16.32
-0.68
8.1
4.14
3.38

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
34,261
33,562
41,131
LT Borrowings
15,463
15,400
15,400
LT Finance Leases
806
652
475
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
18
18
Market Capitalization
131,355
192,484
161,919

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
47,344
44,378
55,436
Cash, Cash Equivalents & STI
3,739
2,669
3,627
Accounts Receivable, Net
19,781
16,965
19,838
Inventories
21,596
20,765
28,454
Total Current Liabilities
48,789
47,692
59,355
Payables & Accruals
- -
- -
- -
ST Debt
34,261
33,562
41,131
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
29.6%
9.19%
4.67%
Free Cash Flow
-98.43%
-162.21%
-243.39%
Net Income, GAAP
-1,041.63%
-301.23%
-45.6%
Sales/Revenue/Turnover
10.57%
11.6%
8.65%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
34,097
41,261
33,535
29,842
138,735
2025
36,591
43,886
39,638
30,619
150,735
2026
36,955
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-193
64
295
996.56
1,162
2025
177
-8.95
455.1
8.68
632
2026
65.98
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Hong-Sik Jang
Full Time Employees
96
Sector
Distribution services
Industry
Electronics distributors
Address
Seongnam-si South Korea
IPO Date
Jul 18, 1997
Business
Wonik Corporation is a South Korea-based diversified company engaged primarily in the distribution of advanced medical devices and industrial materials, the manufacture of electronic components, and the development of derma-cosmetics. Founded in 1983 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, the company serves as the foundational enterprise of the Wonik Group and is publicly listed on the KOSDAQ market under the ticker symbol 032940. The company organizes its business activities into three core operating segments: Medical and Trading, Electronic Components, and Leisure. Through its Medical and Trading division, which constitutes the majority of corporate revenue, Wonik Corporation imports, markets, and distributes specialized healthcare equipment and industrial raw materials. Its healthcare portfolio comprises aesthetic and surgical laser systems; urological, dermatological, and endoscopic medical devices; diagnostic instruments; and clinical consumables supplied to domestic hospitals, clinics, and research institutions through long-standing distribution partnerships with international equipment manufacturers. Through its majority-owned subsidiary CMS Lab Co., Ltd., the company develops and markets functional derma-cosmetic skincare products under established brand names including Cell Fusion C, Cell Fusion C Expert, and Suiskin, targeting both professional clinical channels and global retail consumers. In industrial trading, the company supplies high-purity fused quartz raw materials, ingots, and tubing utilized in semiconductor and display fabrication, alongside specialty industrial lighting equipment, ultraviolet lamps, and optical components. Through its Electronic Components division, Wonik Corporation designs and manufactures custom electronic solutions, including thick-film hybrid integrated circuits (HICs); ceramic substrates; automotive and industrial pressure sensors; ultrasonic transducers; and specialized power control modules for consumer electronics, automotive assemblies, and industrial automation systems. The company also operates a leisure division that manages specialized sports and recreational facilities. Geographically, Wonik Corporation operates primarily across South Korea while maintaining export and distribution networks spanning mainland China, Japan, Southeast Asia, Europe, and the Americas for its electronic components, quartz materials, and derma-cosmetic skincare lines. In recent strategic developments, Wonik Corporation has executed operational and capital restructuring initiatives to enhance shareholder value and accelerate high-margin business growth. In July 2025, the company implemented a formal treasury share retirement program to optimize its capital structure and enhance equity returns. Operationally, the company has expanded the international distribution footprint of its derma-cosmetic business, scaling the presence of the Cell Fusion C brand across major East Asian and Western e-commerce and retail channels while launching upgraded clinical sun-care and barrier-repair formulations. Concurrently, Wonik Corporation has broadened its medical device portfolio by securing extended distribution agreements for next-generation minimally invasive surgical and dermatological laser systems, while streamlining internal manufacturing processes in its electronic sensor and hybrid IC units to meet growing demand from industrial automation and automotive electronics clients.